Get the Stockscreener App
1.47
1.34%
-0.02
Pre-market:
1.64
0.17
+11.56%
Novabridge Biosciences Adr stock is traded at $1.47, with a volume of 567.80K.
It is down -1.34% in the last 24 hours and down -19.23% over the past month.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
See More
Previous Close:
$1.49
Open:
$1.51
24h Volume:
567.80K
Relative Volume:
0.63
Market Cap:
$170.00M
Revenue:
$232.79M
Net Income/Loss:
$-88.69M
P/E Ratio:
-3.3265
EPS:
-0.4419
Net Cash Flow:
-
1W Performance:
-5.77%
1M Performance:
-19.23%
6M Performance:
-63.88%
1Y Performance:
+0.00%
1-Day Range:
$1.46
$1.5495
1-Week Range:
$1.46
$1.64
52-Week Range:
$1.46
$5.19
Novabridge Biosciences Adr Stock (NBP) Company Profile
Name
Novabridge Biosciences Adr
Sector
Industry
Phone
-
Address
-
Compare NBP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBP
Novabridge Biosciences Adr
|
1.47 | 170.00M | 232.79M | -88.69M | 0 | -0.4419 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Novabridge Biosciences Adr Stock (NBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-26 | Resumed | H.C. Wainwright | Buy |
| Oct-03-25 | Initiated | Leerink Partners | Outperform |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Dec-09-21 | Initiated | Siebert Williams Shank | Buy |
| Jun-02-21 | Initiated | Daiwa Securities | Buy |
| Mar-15-21 | Initiated | Needham | Buy |
| Mar-03-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-25-21 | Initiated | Piper Sandler | Overweight |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-20 | Initiated | China Renaissance | Buy |
| Feb-11-20 | Initiated | Jefferies | Buy |
View All
Novabridge Biosciences Adr Stock (NBP) Latest News
Number of shareholders of NovaBridge Biosciences Sponsored ADR – GETTEX:0VY - TradingView
NovaBridge Biosciences SVP Claire Xu sells $13,766 in shares By Investing.com - Investing.com India
NovaBridge Biosciences SVP Claire Xu sells $13,766 in shares - Investing.com
Sean Cao, NovaBridge Biosciences chief BD officer, sells $42,584 in shares - Investing.com
TradingKey - TradingKey
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
NovaBridge Biosciences president buys $577,300 in company shares By Investing.com - Investing.com India
NovaBridge Biosciences president buys $577,300 in company shares - Investing.com
NovaBridge appoints Mark Hagler as president, chief commercial officer - Investing.com
NovaBridge Biosciences (NASDAQ: NBP) posts 2025 loss, extends cash runway to 2028 - Stock Titan
H.C. Wainwright reiterates NovaBridge stock rating on FDA feedback - Investing.com India
NovaBridge gets FDA nod for accelerated approval path for givastomig - Investing.com
NovaBridge reports positive Phase 2a data for eye disease drug - Investing.com
NovaBridge to present Phase 2a data for wet AMD treatment VIS-101 - Investing.com India
NovaBridge enrolls first patient in phase 2 gastric cancer study By Investing.com - Investing.com India
NovaBridge enrolls first patient in phase 2 gastric cancer study - Investing.com
NovaBridge Biosciences stock price target raised to $9 by H.C. Wainwright - Investing.com Nigeria
NBP Stock Price and Chart — NASDAQ:NBP - TradingView
NovaBridge chairman to purchase up to $5 million in company shares By Investing.com - Investing.com Nigeria
NovaBridge chairman to purchase up to $5 million in company shares - Investing.com
Brookline Capital reiterates Buy rating on NovaBridge stock with $8 target By Investing.com - Investing.com South Africa
Brookline Capital reiterates Buy rating on NovaBridge stock with $8 target - Investing.com Nigeria
NovaBridge stock soars after positive gastric cancer drug results - Investing.com
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026 - GlobeNewswire Inc.
Understanding RRC’s financial ratios: A beginner’s guide - uspostnews.com
NovaBridge Biosciences. ADR’s results are impressive - uspostnews.com
NovaBridge to present extended dosing data for cancer drug ragistomig - Investing.com
Evercore ISI resumes Aura Biosciences stock coverage with Outperform rating - Investing.com
What is the current Price Target and Forecast for NovaBridge Biosciences (NBP) - Zacks Investment Research
NovaBridge Biosciences Share Price ADS SPON - Hargreaves Lansdown
NovaBridge Biosciences (0VY.F) stock price, news, quote and history - Yahoo Finance Singapore
NBP Financial Statements & ChartsNovabridge Biosciences.Adr MacroTrends - CMLviz
NBP Interactive Stock ChartNovabridge Biosciences.Adr. Stock Analysis - CMLviz
NBP Pivot Points, Technical Analysis and Moving AveragesNovabridge Biosciences.Adr Technicals - CMLviz
What date does NovaBridge Biosciences's (NBP) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
NBP Stock Price | Analyst Target 9.00 & Consensus - eToro
symbol__ Stock Quote Price and Forecast - CNN
NovaBridge Biosciences Sponsored ADR Earnings and Revenue – NASDAQ:NBP - TradingView — Track All Markets
IMAB Stock Price, Quote & Chart | I-MAB-SPONSORED ADR (NASDAQ:IMAB) - ChartMill
I-Mab stock reaffirmed as Buy at H.C. Wainwright on positive cancer drug data - Investing.com
I-Mab stock price target raised to $9 from $7 at BTIG on strategic shift - Investing.com
I-Mab to rebrand as NovaBridge Biosciences, plans Hong Kong IPO - Investing.com
IMAB SEC FilingsI-Mab 10-K, 10-Q, 8-K Forms - Stock Titan
IMAB Stock Price, News & Analysis - Stock Titan
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Most VolatileStock ScreenerNews - Finviz
Morningstar’s Best- and Worst-Performing Stocks: 2022 - Morningstar
10 of the Cheapest Stocks of 2022 - Morningstar
Invesco NASDAQ Future Gen 200 ETF Holdings - Quiver Quantitative
The Best- and Worst-Performing Stocks: Q3 2022 - Morningstar
New 5-Star Stocks - Morningstar
Novabridge Biosciences Adr Stock (NBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novabridge Biosciences Adr Stock (NBP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cao Sean Wuxiong | See Remarks |
May 14 '26 |
Sale |
1.99 |
21,399 |
42,584 |
35,073 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):